Abstract
Background: Breast cancer is a major cause of death among women worldwide. Treatment for breast cancer involves the surgical removal of cancer tissue, followed by chemotherapy. Although the treatment is efficient, especially when the cancer is detected early, recurrence is common and is often resistant to the previous treatment. Therefore, a constant search for efficient and novel drugs for the treatment of breast cancer is mandatory. Recently, triazole derivatives have shown promising effects against different types of cancer, revealing these molecules as putative anticancer drugs.
Experimental: We have synthesized a series of naphthotriazolyl-4-oxoquinoline derivatives and tested their activity against a human breast cancer cell line. Among the compounds tested, we identified a molecule that killed the human breast cancer cell line MCF-7 with minimal effects on its noncancer counterpart, MCF10A. This effect was seen after 24 hours of treatment and persisted for additional 24 hours after treatment withdrawal. After 1 hour of treatment, the compound, here named 12c, promoted a decrease in cell glucose consumption and lactate production. Moreover, the cells treated with 12c for 1 hour showed diminished intracellular ATP levels with unaltered mitochondrial potential and increased reactive oxygen species production. Additionally, apoptosis was triggered after treatment with the drug for 1 hour. All of these effects are only observed with MCF-7 cells, and not MCF10A. These data show that 12c has selective activity against breast cancer cells and is a potential candidate for a novel anticancer drug.
Results and Conclusion: The naphthotriazolyl-4-oxoquinoline derivatives were obtained in good to moderate yields, and one of them, 12c, exhibited strong and selective antitumor properties. The antitumor mechanism involves inhibition of glycolysis, diminished intracellular ATP levels, induction of ROS production and triggering of apoptosis. These effects are all selective for cancer cells, since noncancer cells are unaffected, and these effects can only be attributed to the whole molecule, as different pharmacophoric groups did not reproduce these effects.
Keywords: Naphthoquinone, Lapachol, 4-quinolone, 1, 2, 3-triazoles, MCF-7, MCF10A.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:A Novel Naphthotriazolyl-4-oxoquinoline Derivative that Selectively Controls Breast Cancer Cells Survival Through the Induction of Apoptosis
Volume: 18 Issue: 17
Author(s): Jessica R. Branco, Vanessa G. Oliveira, Amanda M. Esteves, Ingrid C. Chipoline, Miriam F.O. Lima, Fernanda C.S. Boechat, Fernando C. da Silva, Vítor F. Ferreira, Mauro Sola-Penna, Maria C.B.V. de Souza*Patricia Zancan*
Affiliation:
- Programa de Pos-Graduacao em Quimica, Instituto de Quimica, Universidade Federal Fluminense, Niteroi, RJ,Brazil
- Laboratorio de Oncobiologia Molecular (LabOMol), Departamento de Biotecnologia Farmaceutica, Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, RJ,Brazil
Keywords: Naphthoquinone, Lapachol, 4-quinolone, 1, 2, 3-triazoles, MCF-7, MCF10A.
Abstract: Background: Breast cancer is a major cause of death among women worldwide. Treatment for breast cancer involves the surgical removal of cancer tissue, followed by chemotherapy. Although the treatment is efficient, especially when the cancer is detected early, recurrence is common and is often resistant to the previous treatment. Therefore, a constant search for efficient and novel drugs for the treatment of breast cancer is mandatory. Recently, triazole derivatives have shown promising effects against different types of cancer, revealing these molecules as putative anticancer drugs.
Experimental: We have synthesized a series of naphthotriazolyl-4-oxoquinoline derivatives and tested their activity against a human breast cancer cell line. Among the compounds tested, we identified a molecule that killed the human breast cancer cell line MCF-7 with minimal effects on its noncancer counterpart, MCF10A. This effect was seen after 24 hours of treatment and persisted for additional 24 hours after treatment withdrawal. After 1 hour of treatment, the compound, here named 12c, promoted a decrease in cell glucose consumption and lactate production. Moreover, the cells treated with 12c for 1 hour showed diminished intracellular ATP levels with unaltered mitochondrial potential and increased reactive oxygen species production. Additionally, apoptosis was triggered after treatment with the drug for 1 hour. All of these effects are only observed with MCF-7 cells, and not MCF10A. These data show that 12c has selective activity against breast cancer cells and is a potential candidate for a novel anticancer drug.
Results and Conclusion: The naphthotriazolyl-4-oxoquinoline derivatives were obtained in good to moderate yields, and one of them, 12c, exhibited strong and selective antitumor properties. The antitumor mechanism involves inhibition of glycolysis, diminished intracellular ATP levels, induction of ROS production and triggering of apoptosis. These effects are all selective for cancer cells, since noncancer cells are unaffected, and these effects can only be attributed to the whole molecule, as different pharmacophoric groups did not reproduce these effects.
Export Options
About this article
Cite this article as:
Branco R. Jessica , Oliveira G. Vanessa , Esteves M. Amanda, Chipoline C. Ingrid , Lima F.O. Miriam , Boechat C.S. Fernanda , da Silva C. Fernando , Ferreira F. Vítor , Sola-Penna Mauro , de Souza C.B.V. Maria *, Zancan Patricia*, A Novel Naphthotriazolyl-4-oxoquinoline Derivative that Selectively Controls Breast Cancer Cells Survival Through the Induction of Apoptosis, Current Topics in Medicinal Chemistry 2018; 18 (17) . https://dx.doi.org/10.2174/1568026618666180821142458
DOI https://dx.doi.org/10.2174/1568026618666180821142458 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Current Pharmaceutical Design Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer
Current Medicinal Chemistry Inflammation, Serotonin and Major Depression
Current Drug Targets Nanocarriers to Solid Tumors: Considerations on Tumor Penetration and Exposure of Tumor Cells to Therapeutic Agents
Current Pharmaceutical Biotechnology Targeting: The ADEPT Story So Far
Current Drug Targets Extracts and Flavonoids of <i>Passiflora</i> Species as Promising Anti-inflammatory and Antioxidant Substances
Current Pharmaceutical Design Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science Patent Selections
Recent Patents on Regenerative Medicine Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Graphical Abstracts
Medicinal Chemistry Two Branched Polar Groups and Polar Linker Moieties of Thiophene Amide Derivatives Are Essential for MRP2/ABCC2 Recognition
Drug Metabolism Letters Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Outcome-Dependent Global Similarity Analysis of Imbalanced Core Signaling Pathways in Ischemic Mouse Hippocampus
CNS & Neurological Disorders - Drug Targets Novel Applications of the Paired-End diTag (PET) Technology in Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Meet Our Editorial Board Member
Current Cancer Drug Targets Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Docking and Virtual Screening to Identify PKC Agonists: Potentials in Anticancer Therapeutics
Current Computer-Aided Drug Design